Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00089011
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇺🇸LDS Hospital, Salt Lake City, Utah, United States
🇺🇸Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00089037
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00002831
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 720
- Registration Number
- NCT00087581
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004878
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2004-03-08
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00006350
- Locations
- 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004904
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
- Conditions
- Interventions
- First Posted Date
- 2004-03-02
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 10
- Registration Number
- NCT00078559
- Locations
- 🇺🇸
University of Wisconsin - Department of Medicine, Madison, Wisconsin, United States
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
- Conditions
- First Posted Date
- 2004-02-20
- Last Posted Date
- 2014-05-02
- Target Recruit Count
- 20
- Registration Number
- NCT00003572
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2013-10-16
- Target Recruit Count
- 31
- Registration Number
- NCT00076570
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.